FDA approves epcoritamab, a first-in-class bispecific antibody, for relapsed or refractory large B-cell lymphoma

Evidence stage: Later-Stage HumanRegulatory status: FDA-approved for the exact stated cancer/useGuideline status: Not addressed

The FDA granted accelerated approval to epcoritamab-bysp (Epkinly), a subcutaneously-injected CD3xCD20 bispecific antibody, for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified — including DLBCL arising from an indolent lymphoma — and high-grade B-cell lymphoma, after two or more prior lines of systemic therapy. Epcoritamab works by simultaneously binding CD20 on lymphoma cells and CD3 on the patient’s own T-cells, physically bringing them together so the T-cells attack the cancer cells directly, without requiring the weeks-long individualized manufacturing process CAR T-cell therapies need. The approval was supported by the dose-expansion cohort of the open-label, single-arm, phase 1/2 EPCORE NHL-1 trial (ClinicalTrials.gov NCT03625037; primary publication in the Journal of Clinical Oncology, DOI 10.1200/JCO.22.01725, PMID 36548927), which enrolled 157 patients with relapsed or refractory large B-cell lymphoma and reported an objective response rate of 63.1%, including a 38.9% complete response rate. The prescribing information carries a boxed warning for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), both known risks of this drug class.

What This Means

In the single-arm, phase 1/2 EPCORE NHL-1 trial, epcoritamab — a subcutaneously-injected bispecific antibody that physically brings a patient's own T-cells into contact with lymphoma cells — produced an objective response in 63.1% of heavily pretreated patients with relapsed or refractory large B-cell lymphoma, including a 38.9% complete response rate, supporting FDA accelerated approval.

What This Doesn't Mean

This is a single-arm trial with no randomized comparison group, the basis for an ACCELERATED approval, not yet full/traditional approval — continued approval may depend on results from a confirmatory randomized trial. This record makes no claim about epcoritamab's effect on overall survival compared with other treatments, which this trial design cannot establish.

Why It Matters

A bispecific antibody that can be given "off the shelf" — without the weeks-long, per-patient manufacturing process CAR T-cell therapies require — gives lymphoma patients a genuinely different, more immediately accessible T-cell-engaging treatment option, in a cancer type — lymphoma — that had zero coverage on this site before this record.

Promise & Proof

Proof — strength of the evidence 5 / 5
  • Base score from evidence stage: Later-Stage Human.
  • FDA-approved for the exact stated cancer/use.
Promise — potential significance if later evidence holds up 3 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or other large B-cell lymphoma after two or more prior lines of systemic therapy, enrolled in the dose-expansion cohort of the single-arm, open-label, phase 1/2 EPCORE NHL-1 trial. (Adults)

Carries an FDA boxed warning for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), both serious, potentially life-threatening risks requiring specialized monitoring, particularly around the first doses. This record does not itself detail the full safety/step-up dosing protocol and that should be added before publication.

Full evidence details
Study design
Non-randomized trial
Sample size
157

Funding & Conflicts

Sponsor/developer: Genmab A/S, co-developed and co-commercialized with AbbVie — not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status
FDA-approved for the exact stated cancer/use
Indication
Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma) and high-grade B-cell lymphoma, after two or more lines of systemic therapy.
Biomarker requirement
CD20-expressing B-cell lymphoma (target of the bispecific antibody; not a patient-selection biomarker test)
Decision date
2023-05-19
Access notes
Requires a step-up dosing schedule and monitoring for cytokine release syndrome, particularly around the first doses.
Source
Regulator record (opens in a new tab)

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Additional context

Why Should I Trust This?

  • 1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
  • Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "Legacy / Unverified" to "In editorial review".
  2. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

FDA approves epcoritamab, a first-in-class bispecific antibody, for relapsed or refractory large B-cell lymphoma

https://cancerdiscoveries.com/discoveries/fda-approves-epcoritamab-a-first-in-class-bispecific-antibody-for-relapsed-or-refractory-large-b-cell-lymphoma/

Evidence stage: Later-Stage Human

What This Means

In the single-arm, phase 1/2 EPCORE NHL-1 trial, epcoritamab — a subcutaneously-injected bispecific antibody that physically brings a patient's own T-cells into contact with lymphoma cells — produced an objective response in 63.1% of heavily pretreated patients with relapsed or refractory large B-cell lymphoma, including a 38.9% complete response rate, supporting FDA accelerated approval.

What This Doesn't Mean

This is a single-arm trial with no randomized comparison group, the basis for an ACCELERATED approval, not yet full/traditional approval — continued approval may depend on results from a confirmatory randomized trial. This record makes no claim about epcoritamab's effect on overall survival compared with other treatments, which this trial design cannot establish.

Why It Matters

A bispecific antibody that can be given "off the shelf" — without the weeks-long, per-patient manufacturing process CAR T-cell therapies require — gives lymphoma patients a genuinely different, more immediately accessible T-cell-engaging treatment option, in a cancer type — lymphoma — that had zero coverage on this site before this record.

Primary sources

  • Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial (Journal of Clinical Oncology) — https://doi.org/10.1200/JCO.22.01725 (DOI 10.1200/JCO.22.01725, PMID 36548927)

Date verified: 2026-08-13

Correction status: No correction or retraction